A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1409-1418

  Gulley, James L ^a   Madan, Ravi A ^a   Tsang, Kwong Yok ^a   Arlen, Philip M ^a   Camphausen, Kevin ^a   Mohebtash, Mahsa ^a   Kamrava, Mitchell ^a   Schlom, Jeffrey ^a   Citrin, Deborah ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CEA TRICOM; Fowlpox; Immunotherapy; Poxviral vector; Therapeutic vaccine; Vaccinia

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VACCINIA VACCINE; VIRUS VECTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOWLPOX VIRUS; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; RADIATION DOSE; RECTUM CANCER; T LYMPHOCYTE;

ADULT; AGED; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FOWLPOX VIRUS; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); PILOT PROJECTS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VACCINES, SYNTHETIC;

EID: 80053638936     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.615741     Document Type: Article

References (52)

1. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;11:327-34 (Pubitemid 19112371)
2. Robbins PF, Eggensperger D, Qi CF, Schlom J. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53:892-7 (Pubitemid 23119531)
3. Tendler A, Kaufman HL, Kadish AS. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum Pathol 2000;31:1357-62
4. Ilantzis C, DeMarte L, Screaton RA, Stanners CP. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 2002;4:151-63 (Pubitemid 34218683)
5. Hostetter RB, Campbell DE, Chi KF, et al. Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. Arch Surg 1990;125:300-4 (Pubitemid 20079068)
6. Mori F, Giannetti P, Peruzzi D, et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther 2009;20:125-36
7. Cho HI, Kim HJ, Oh ST, Kim TG. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003;22:224-36
8. Babatz J, Rollig C, Lobel B, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006;55:268-76 (Pubitemid 41682575)
9. Madan RA, Bilusic M, Hodge JW, et al. A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA [abstract]. ASCO Annual Meeting; 2011. p. 2604
10. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002;62:6944-51 (Pubitemid 35424085)
11. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4:575-88 (Pubitemid 38480556)
12. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7 (Pubitemid 35204734)
13. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505 (Pubitemid 32685780)
14. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7
15. Kantor J, Abrams S, Irvine K, et al. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann N Y Acad Sci 1993;690:370-3 (Pubitemid 23278732)
16. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83 (Pubitemid 29076067)
17. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-68 (Pubitemid 27240492)
18. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73
19. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31 (Pubitemid 46224171)
20. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90
21. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008;22:1064-70; discussion 1075, 1080-1081, 1084
22. Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009;11:37-42
23. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94 (Pubitemid 39446933)
24. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37 (Pubitemid 38802440)
25. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62 (Pubitemid 40627887)
26. Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91
27. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional Phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-8
28. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005;15:279-83 (Pubitemid 41377144)
29. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96 (Pubitemid 351521864)
30. Zaremba S, Barzaga E, Zhu M, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7 (Pubitemid 27441063)
31. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9
32. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40 (Pubitemid 351302548)
33. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25 (Pubitemid 35155034)
34. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
35. Nakayama Y, Sako T, Shibao K, et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 2002;22:2437-42 (Pubitemid 34857079)
36. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002;86:417-23 (Pubitemid 34185127)
37. Morse M, Niedzwiecki D, Marshall JL, et al. Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls [abstract]. ASCO Annual Meeting; 2011. p-3557
38. Lyerly H, Hobeika A, Niedzwiecki D, et al. A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study [sbstract]. ASCO Annual Meeting; 2011. p. 2533
39. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91 (Pubitemid 32708668)
40. Fu T, Shen Y, Fujimoto S. Tumor-specific CD4+ suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-7 (Pubitemid 30620411)
41. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44 (Pubitemid 39255944)
42. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-40 (Pubitemid 32703105)
43. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6 (Pubitemid 34441324)
44. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-51 (Pubitemid 350075011)
45. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40 (Pubitemid 46345506)
46. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
47. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74
48. Gulley J, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011;18:e150-7
49. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97
50. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28:495-504 (Pubitemid 17074172)
51. Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother 2006;7:1475-86 (Pubitemid 44173209)
52. National Cancer Institute (NCI). 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer. ClinicalTrials.gov NCT00450619; Available from http://clinicaltrials.gov/ct2/ show/NCT00450619? term=NCT00450619&rank=1